ODYSSEY OUTCOMES
2018
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
In 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).
Result
Efficacy: Composite of CHD death, nonfatal MI, ischaemic stroke, or unstable angina requiring hospitalisationHR 0.85 (95% CI 0.78-0.93) · P < 0.001
Below 1 favours alirocumab, above 1 favours placebo.
- Absolute difference
- 1.6 points
- NNT
- 63
Absolute difference and NNT are derived from the event rates.
Also reported: All-cause death lower (3.5% vs 4.1%; HR 0.85, 95% CI 0.73-0.98), greatest benefit with baseline LDL-C ≥100 mg/dL.
- Subtopic
- PCSK9 inhibitor
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSESC 2023 ACSESC/EAS LipidsESC 2021 PreventionACC/AHA 2025 ACSACC/AHA 2023 CCDACC/AHA 2026 Dyslipidaemia
- Source
- Schwartz GG, et al. N Engl J Med. 2018;379(22):2097-2107.doi 10.1056/NEJMoa1801174
Discussion & critique
Benefit concentrated in patients with higher baseline LDL-C, and absolute risk reduction was modest. Informs guidelines to reserve PCSK9 inhibitors for very-high-risk post-ACS patients not at LDL goal on maximally tolerated statin/ezetimibe.